Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Renal cell carcinoma treatment, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, and Multiple Myeloma Research and Treatments.
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.
Impact of Chemotherapy on Sperm Functional Characteristics in Patients With Testicular Germ Cell Tumours.
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer.
Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry.
Relugolix in Combination with Androgen Receptor Pathway Inhibitors in the Treatment of Metastatic Prostate Cancer: A Clinical Perspective.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the <scp>CLEAR</scp> trial
Fecal miRNA profiles in colorectal cancers with mucinous morphology
Fecal miRNA profiles in colorectal cancers with mucinous morphology
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma.
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study.
TElomeric repeat-containing RNA (TERRA): Physiological functions and relevance in cancer
Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis.
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.
Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases.
Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib.
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients.
Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib.
Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice.
DNA Repair Capacity and Response to Treatment of Colon Cancer
Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis.
Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients
Tumour devascularisation as a potential immunotherapeutic strategy.
Bleomycin‐induced chromosomal damage and shortening of telomeres in peripheral blood lymphocytes of incident cancer patients
Single Nucleotide Polymorphisms within Interferon Signaling Pathway Genes Are Associated with Colorectal Cancer Susceptibility and Survival